Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1986 1
1989 1
1995 2
1999 1
2000 1
2003 5
2004 2
2005 1
2006 1
2007 4
2009 3
2010 2
2011 6
2012 8
2013 6
2014 9
2015 6
2016 3
2017 6
2018 12
2019 14
2020 8
2021 14
2022 15
2023 17
2024 17
2025 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and classification of optic neuritis.
Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov MM, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi PA, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, de Seze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Tilikete CF, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Martínez-Lapiscina EH, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales AJ, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, van Pesch V, Wang AG, Wattjes MP, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT. Petzold A, et al. Among authors: sa mj. Lancet Neurol. 2022 Dec;21(12):1120-1134. doi: 10.1016/S1474-4422(22)00200-9. Epub 2022 Sep 27. Lancet Neurol. 2022. PMID: 36179757 Review.
Gluten chorea.
Andrade C, Rocha H, Albuquerque A, Sá MJ. Andrade C, et al. Among authors: sa mj. Clin Neurol Neurosurg. 2015 Nov;138:8-9. doi: 10.1016/j.clineuro.2015.07.009. Epub 2015 Jul 17. Clin Neurol Neurosurg. 2015. PMID: 26209754 No abstract available.
Explainable time-to-progression predictions in multiple sclerosis.
D'hondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, Havrdova EK, Lugaresi A, Weinstock-Guttman B, Mrabet S, Lalive P, Kermode AG, Ozakbas S, Patti F, Prat A, Tomassini V, Roos I, Alroughani R, Gerlach O, Khoury SJ, van Pesch V, Sá MJ, Prevost J, Spitaleri D, McCombe P, Solaro C, van der Walt A, Butzkueven H, Laureys G, Sánchez-Menoyo JL, de Gans K, Al-Asmi A, Deri N, Csepany T, Al-Harbi T, Carroll WM, Rozsa C, Singhal B, Hardy TA, Ramanathan S, Peeters L, Vens C; MSBase Study Group. D'hondt R, et al. Among authors: sa mj. Comput Methods Programs Biomed. 2025 May;263:108624. doi: 10.1016/j.cmpb.2025.108624. Epub 2025 Feb 6. Comput Methods Programs Biomed. 2025. PMID: 39965473
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
Foong YC, Merlo D, Gresle M, Buzzard K, Zhong M, Yeh WZ, Jokubaitis V, Monif M, Skibina O, Ozakbas S, Patti F, Grammond P, Amato MP, Kalincik T, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Lechner Scott J, Boz C, Sa MJ, Butzkueven H, van der Walt A, Zhu C; MSBASE study group. Foong YC, et al. Among authors: sa mj. J Neurol Neurosurg Psychiatry. 2024 Jul 15;95(8):767-774. doi: 10.1136/jnnp-2023-332883. J Neurol Neurosurg Psychiatry. 2024. PMID: 38453478
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Among authors: sa mj. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39442037 Free PMC article.
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group; Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T, Granziera C. Müller J, et al. Among authors: sa mj. JAMA Neurol. 2025 Jun 1;82(6):614-625. doi: 10.1001/jamaneurol.2025.0495. JAMA Neurol. 2025. PMID: 40227706
Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort.
Chien C, Cruz E Silva V, Geiter E, Meier D, Zimmermann H, Bichuetti DB, Idagawa MI, Altintas A, Tanriverdi U, Siritho S, Pandit L, Dcunha A, Sá MJ, Figueiredo R, Qian P, Tongco C, Lotan I, Khasminsky V, Hellmann MA, Stiebel-Kalish H, Rotstein DL, Waxman L, Ontaneda D, Nakamura K, Abboud H, Subei MO, Mao-Draayer Y, Havla J, Asgari N, Skejø PB, Kister I, Ringelstein M, Broadley S, Arnett S, Marron B, Jolley AM, Wunderlich M, Green S, Cook LJ, Yeaman MR, Smith TJ, Brandt AU, Wuerfel J, Paul F; Guthy-Jackson Charitable Foundation International Clinical Consortium for NMOSD. Chien C, et al. Among authors: sa mj. Radiology. 2024 Nov;313(2):e233099. doi: 10.1148/radiol.233099. Radiology. 2024. PMID: 39530897 Free PMC article.
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Müller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, Patti F, Grammond P, Buzzard K, Skibina O, Prat A, Girard M, Grand'Maison F, Alroughani R, Lechner-Scott J, Spitaleri D, Barnett M, Cartechini E, Sa MJ, Gerlach O, van der Walt A, Butzkueven H, Prevost J, Castillo-Triviño T, Yamout B, Khoury SJ, Yaldizli Ö, Derfuss T, Granziera C, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group. Müller J, et al. Among authors: sa mj. CNS Drugs. 2025 Apr;39(4):403-416. doi: 10.1007/s40263-025-01164-w. Epub 2025 Feb 14. CNS Drugs. 2025. PMID: 39953338 Free PMC article.
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, Levy M, Weinshenker BG, Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; Guthy Jackson International Clinical Consortium*. Arnett S, et al. J Neurol. 2024 Aug;271(8):4794-4812. doi: 10.1007/s00415-024-12452-8. Epub 2024 Jul 3. J Neurol. 2024. PMID: 38958756 Free PMC article.
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, Prat A, Girard M, Duquette P, Izquierdo G, Eichau S, Grammond P, Boz C, Kalincik T, Blanco Y, Buzzard K, Skibina O, Sa MJ, van der Walt A, Butzkueven H, Terzi M, Gerlach O, Grand'Maison F, Foschi M, Surcinelli A, Barnett M, Lugaresi A, Onofrj M, Yamout B, Khoury SJ, Prevost J, Lechner-Scott J, Maimone D, Amato MP, Spitaleri D, Van Pesch V, Macdonell R, Cartechini E, de Gans K, Slee M, Castillo-Triviño T, Soysal A, Sanchez-Menoyo JL, Laureys G, Van Hijfte L, McCombe P, Altintas A, Weinstock-Guttman B, Aguera-Morales E, Etemadifar M, Ramo-Tello C, John N, Turkoglu R, Hodgkinson S, Besora S, Van Wijmeersch B, Fernandez-Bolaños R, Patti F; MSBase Study Group. Toscano S, et al. Among authors: sa mj. Neurotherapeutics. 2025 Mar;22(2):e00552. doi: 10.1016/j.neurot.2025.e00552. Epub 2025 Feb 17. Neurotherapeutics. 2025. PMID: 39965993 Free PMC article.
160 results